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ABSTRACT
Dermanyssus gallinae, the poultry red mite, is a global threat to the commercial egg-laying
industry. Control of D. gallinae is difficult, with only a limited number of effective pesticides
and non-chemical treatments available. Here, we characterize the candidate vaccine antigen
D. gallinae cathepsin D-1 (Dg-CatD-1) and demonstrate that purified refolded recombinant
Dg-Cat-D1 (rDg-CatD-1) is an active aspartyl proteinase which digests haemoglobin with a
pH optimum of pH 4. Soluble protein extracts from D. gallinae also have haemoglobinase
activity, with a pH optimum comparable to the recombinant protein, and both proteinase
activities were inhibited by the aspartyl proteinase inhibitor Pepstatin A. Enzyme activity and
the ubiquitous localization of Dg-CatD-1 protein in sections of adult female mites is
consistent with Dg-CatD-1 being a lysosomal proteinase. Using Dg-CatD-1 as a model
vaccine antigen, we compared vaccine delivery methods in laying hens via vaccination with:
(i) purified rDg-CatD-1 with Montanide™ ISA 71 VG adjuvant; (ii) recombinant DNA vaccines
for expression of rDg-CatD-1 and (iii) transgenic coccidial parasite Eimeria tenella expressing
rDg-CatD-1. In two independent trials, only birds vaccinated with rDg-CatD-1 with
Montanide™ ISA 71 VG produced a strong and long-lasting serum anti-rDg-Cat-D1 IgY
response, which was significantly higher than that in control birds vaccinated with adjuvant
only. Furthermore, we showed that egg-laying rates of D. gallinae mites fed on birds
vaccinated with rDg-CatD-1 in Montanide™ ISA 71 VG was reduced significantly compared
with mites fed on unvaccinated birds.
RESEARCH HIGHLIGHTS
. Dermanyssus gallinae cathepsin D-1 (Dg-CatD-1) digests haemoglobin
. Vaccination of hens with rDg-CatD-1 in Montanide™ ISA 71 VG results in long-lasting IgY
levels
. Serum anti-rDg-CatD-1 antibodies reduce egg laying in D. gallinae after a single blood meal
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Introduction
The poultry red mite (PRM),Dermanyssus gallinae (De
Geer) is a blood-feeding ectoparasite that infests many
avian species. Globally, from both economic and wel-
fare perspectives, PRM is the most important parasite
to the egg-laying industry. Across Europe, PRM preva-
lence is high, with up to 83% of commercial egg-laying
facilities infested (George et al., 2015). In Europe alone,
heavy infestations of poultry houses with PRM cost the
industry an estimated 231 million Euro per annum
(Sigognault Flochlay et al., 2017; Van Emous, 2017).
PRM are difficult to control as they live off-host in
inaccessible areas of the poultry house, and emerge
during darkness to feed from birds for up to 1 h
every 2–4 days (Sparagano et al., 2014; George et al.,
2015). Heavy infestations of birds can reach up to
500,000 mites per bird and cause serious welfare issues,
including anaemia, irritation and restlessness as well as
a significant reduction in egg production (Kilpinen
et al., 2005; Sigognault Flochlay et al., 2017). Currently,
PRM populations are controlled during periods when
hen-houses are empty using synthetic acaricides, or
during production cycles using an isoxazoline-based
drug (Sparagano et al., 2014; Miglianico et al., 2018).
However, long-term repeated use of the older classes
of acaricides has resulted in emergence of resistant
PRM populations (Beugnet et al., 1997; Abbas et al.,
2014). In addition, due to concerns about safety and
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environmental contamination, many synthetic acari-
cides have been withdrawn from use, exacerbating
the problem of PRM control (Sparagano et al., 2014).
Vaccination can provide high levels of protection
against blood-feeding ectoparasites, thereby reducing
reliance on chemical control methods (de la Fuente
& Kocan, 2003; Willadsen, 2004). For example, the
commercial cattle vaccines, TickGARD™ and
Gavac™, both based on administration of recombi-
nant Bm86 protein, have been used to protect vacci-
nated cattle against the tick, Rhipicephalus microplus
(Rand et al., 1989; Rodriguez et al., 1995). Moreover,
studies show that vaccination has the potential to con-
trol PRM infestations of chickens. Experimental vacci-
nation with protein extracts from D. gallinae mites
(Harrington et al., 2009; Wright et al., 2009; Bartley
et al., 2015; Makert et al., 2016), or with recombi-
nant-expressed D. gallinae antigens (Bartley et al.,
2009, 2012, 2015; Harrington et al., 2009; Wright
et al., 2016), induces antigen-specific serum IgY that
reduces mite survival when fed to mites in in vitro
feeding devices. Furthermore, we recently showed
that vaccination of laying hens, housed in a commer-
cial-style poultry facility, with a native PRM soluble
protein extract results in protective immunity, redu-
cing average mite counts in cages of vaccinated birds
by 78% compared to cages of control, unvaccinated
birds (Bartley et al., 2017).
Vaccine delivery methodology is particularly salient
in the poultry layer sector. Vaccination programmes
operate at large scales in hatchlings, or immature
hens, and need to induce and sustain effective immu-
nity through the full laying cycle, which commonly
ranges between 60 and 80 weeks. This need for pro-
longed protection is one of the most challenging
aspects of developing vaccines for laying flocks, par-
ticularly for ectoparasites where immunoprotective
vaccine antigens (including Bm86) may be “hidden”
because they are not naturally exposed to the host
immune system during parasite feeding. This means
there is no opportunity for natural immunological
recall responses (boosting) against this type of antigen
when hosts are exposed to the parasite.
In the current study, we used a prototype vaccine
antigen D. gallinae cathepsin D1 (Dg-CatD-1) (Bartley
et al., 2012), and compared antigen delivery to laying
hens by: (i) immunization with purified recombinant
Dg-CatD-1 in adjuvant; (ii) recombinant DNA vacci-
nation for expression of Dg-CatD-1 and (iii) oral chal-
lenge with populations of the live transgenic coccidial
parasite Eimeria tenella expressing Dg-CatD-1. These
delivery platforms were chosen to compare antigen-
specific antibody titres in laying hens using tried and
tested protein-in-adjuvant vaccination (Bartley et al.,
2017), with new vaccine technologies which include
DNA vaccination (Gupta et al., 2016; Meunier et al.,
2016) and a novel experimental E. tenella antigen
delivery system (Clark et al., 2012; Marugan-Hernan-
dez et al., 2016; Pastor-Fernandez et al., 2018), in
order to identify the optimal system. We assessed
each delivery platform for the ability to induce specific
anti-Dg-CatD-1 IgY in laying hens and monitor long-
evity of the response over a commercially relevant
period. With the delivery method that gave the highest
antibody responses and the longest duration of
response, we went on to test vaccine efficacy of the pro-
totype vaccine antigen using a recently-developed
novel in vivo challenge system (Nunn et al., 2019).
Materials and methods
Purification and refolding of recombinant Dg-
CatD-1
Expression of recombinant Dg-CatD-1 (rDg-CatD-1)
was carried out in BL21-CodonPlus®(DE3)-RIPL E. coli
cells as previously described (Bartley et al., 2012). Fol-
lowing expression, cells were lysed by sonication and
the insoluble inclusion bodies were isolated by centrifu-
gation at 13,000×g for 20 min at 4°C. Inclusion bodies
were solubilized in binding buffer (8M urea, 20 mM
Tris-HCl, 0.5M NaCl, 45 mM imidazole, pH8.0) and
rDg-CatD-1 was purified by nickel-affinity chromato-
graphy on HisTrap™ HP columns using an ÄKTA™
chromatography system (GE Healthcare Life Sciences,
Marlborough, MA, USA). rDg-CatD-1 was eluted in
binding buffer with a linear imidazole gradient (up to
500 mM imidazole), within five column volumes.
Fractions containing purified rDg-CatD-1 were
pooled and refolded at 4°C by step-wise dialysis into
refolding buffer (100 mMTris-HCl, 400 mML-arginine,
2 mM EDTA, 0.5 mM oxidized glutathione, 5 mM
reduced glutathione, pH8.0) with decreasing concen-
trations of urea. Briefly, rDg-CatD-1 was contained
within cellulose membrane dialysis tubing (Sigma-
Aldrich Co Ltd, Dorset, UK) and dialyzed for 3 h into
refolding buffer with 6 M urea; 3 h into refolding buffer
with 4 M urea; overnight into refolding buffer with 2 M
urea; 3 h into refolding buffer with 1 M urea; and
finally overnight into 10 mM Tris-HCl (pH 7.4), 0.5 M
NaCl. After refolding, rDg-CatD-1 was concentrated
using a Centriprep® centrifugal filter with Ultracel-10
membrane (Merck, Kenilworth, NJ, USA) followed by
filtration through a 0.2 µm sterile filter (Sartorious, Goet-
tingen, Germany). rDg-CatD-1 protein concentration
was determined by BCA assay (Thermo Fisher Scientific,
Waltham,MA,USA)withBSAstandards, andpuritywas
confirmed by SDS-PAGE analysis. Purified, refolded
rDg-CatD-1 was stored at 4°C prior to use.
Haemoglobin digest assay
Hydrolysis of haemoglobin by purified refolded rDg-
CatD-1 was determined using a haemoglobin digest
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assay, according to Houseman & Downe (1982). As a
positive control, the haemoglobin digest assay was
also performed with a soluble mite extract, with protein
extracts prepared as described previously (Wright
et al., 2009). For each assay, equal volumes of 20 mg/
ml bovine haemoglobin (Sigma-Aldrich Co Ltd, Dor-
set, UK) in 0.15 M NaCl, and a 200 mM buffer of vary-
ing pH (pH 2 glycine-HCl buffer; pH 3–6 citrate buffer;
pH 7 HEPES buffer) were mixed and incubated at 37°C
for 5 min. Digestion was initiated by adding refolded
rDg-CatD-1, or soluble mite extract to the haemo-
globin/buffer mixture and assays were incubated at
37°C for 20 h. Reactions were terminated by addition
of 10% (w/v) trichloroacetic acid (TCA) (final concen-
tration) and precipitated polypeptides were removed
by centrifugation at 13,000 × g for 10 min at 4°C.
Absorbance values of TCA-soluble peptides in super-
natants were measured at 280 nm and used to calculate
enzyme activity. For inhibition assays, a 1 mg/ml pep-
statin A (Sigma-Aldrich Co Ltd, Dorset, UK) stock was
prepared in 10% acetic acid in methanol (9:1 methanol:
acetic acid). Inhibition assays were performed as
described above, in pH 4 citrate buffer, with the
addition of 2 µM pepstatin A (final concentration; con-
trol reactions contained no pepstatin A, but an equiv-
alent volume of 10% acetic acid in methanol). For all
assays, controls lacking test samples were run in paral-
lel and activity data were corrected for any spontaneous
haemoglobin breakdown. One haemoglobin enzyme
unit (Hb.E.U.) is defined as an increase of one absor-
bance unit at 280 nm, per mg protein, per hour.
SDS-PAGE and western blot analysis
Proteins were analysed by SDS-PAGE using the
NuPAGE® electrophoresis system (Thermo Fisher
Scientific, Waltham, MA, USA). Briefly, protein
samples were prepared in NuPAGE LDS sample
buffer with reducing agent and heated to 70°C for
10 min prior to loading on NuPAGE 4–12% Bis-Tris
gels. Gels were run in MES SDS running buffer and
either stained with SimplyBlue™ SafeStain (Thermo
Fisher Scientific, Waltham, MA, USA) or prepared
for western blots.
For western blot analysis, proteins were transferred
to nitrocellulose membranes by electroblotting in 1X
NuPAGE transfer buffer, according to the manufac-
turer’s instructions (Thermo Fisher Scientific, Wal-
tham, MA, USA). After transfer, to prevent non-
specific protein binding, membranes were blocked by
incubation at room temperature for 2 h with 5% (w/
v) milk powder in TBST (20 mM Tris-HCl, pH7.6,
150 mM NaCl, 0.1% (v/v) TWEEN® 20). Blots were
washed three times with TBST, then incubated with
antiserum raised in rabbits against rDg-Cat-D1. Anti-
serum was generated using a custom service provided
by ImmunoTools (Friesoythe, Germany) and used at
1:3000 dilution in 5% milk powder in TBST. After
washing three times in TBST, membranes were incu-
bated with swine anti-rabbit IgG HRP (Agilent, Santa
Clara, CA, USA) at 1:3000 dilution in TBST for 1 h
at room temperature. Membranes were washed three
times with TBST and specifically-bound antibodies
were detected using SIGMAFAST™ 3,3′-Diaminoben-
zidine (DAB) substrate.
Immunohistochemical localization of Dg-CatD-1
in D. gallinae tissues
Mites were collected and stored at room temperature
for 7 days to allow complete digestion of their blood
meal, and then fixed in Carnoy’s fixative (60% absolute
ethanol, 30% chloroform, 10% glacial acetic acid) for 5
days at 4°C. After fixation, mites were washed in
150 mM NaCl then orientated and pre-embedded in
2% agar:2.5% gelatin according to Jones & Calabresi
(2007). Tissues were dehydrated using a graded ethanol
series and then infiltrated with paraffin wax using a
Tissue-Tek VIP 6 AI automated vacuum infiltration
processor (Sakura, Rijn, The Netherlands). After pro-
cessing, tissues were embedded in paraffin wax blocks
and sections of 5 µm thickness were cut and placed
on Superfrost® Plus glass slides (Thermo Fisher Scien-
tific, Waltham, MA, USA). Tissue sections were depar-
affinized in Histo-Clear (National Diagnostics, Atlanta,
GA, USA) and then rehydrated in graded alcohols. Sec-
tions were washed in PBS (137 mMNaCl, 2.7 mMKCl,
8.1 mM Na2HPO4, 1.5 mM KH2PO4) and endogenous
peroxidase was quenched with 3% (v/v) H2O2 at room
temperature for 20 min. Tissue sections were blocked
by incubation in 25% normal goat serum (v/v) (Vector
Laboratories, Burlingame, CA, USA) in PBS with 0.5%
(v/v) TWEEN® 80 (PBST80), then incubated overnight
at 4°C with primary rabbit anti-Dg-CatD-1 antisera at
1:10,000 (final concentration) in 10% (v/v) normal goat
serum in PBST80. Bound antibodies were detected
using EnVision+ System-HRP/DAB (Agilent, Santa
Clara, CA, USA), according to the manufacturer’s
instructions and then counterstained with haematoxy-
lin. Sections incubated with pre-immune rabbit sera
were processed in parallel and used as negative con-
trols. Images of tissue sections were captured on an
Olympus microscope equipped with a CCD camera.
Formulation of rDg-CatD-1 in Montanide™ ISA
71 VG adjuvant
Purified refolded rDg-Cat-D1 protein was formulated
in Montanide™ ISA 71 VG (SEPPIC, Paris, France)
according to manufacturer’s guidelines. Briefly, rDg-
Cat-D1 in 10 mM Tris-HCl (pH7.4), 0.5 M NaCl was
mixed with Montanide™ ISA 71 VG (adjuvant/antigen
ratio of 70:30, based on weight) and a stable water-in-
oil emulsion was produced using an IKA® T25 Ultra
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Turrax® high shear mixer with a S25N-8G head at
15,600 rpm for 3 min. For adjuvant-only control injec-
tions, 10 mM Tris-HCl (pH 7.4), 0.5 M NaCl was
mixed with Montanide™ ISA 71 VG and processed
as described above.
Preparation of IL21::Dg-CatD-1::mCherry DNA
Vaccine
Three synthetic IL21::Dg-CatD-1::mCherry fusion
genes were designed for DNA vaccination and syn-
thesized by GeneArt gene synthesis (Thermo Fisher
Scientific, Waltham, MA, USA). Each synthetic gene
contained a continuous open reading frame, and
encoded sequence variants of the following fusion part-
ners: (i) Gallus gallus IL-21 (NM_001024835); (ii) Dg-
CatD-1 (HE565350); and (iii) fluorescent reporter
mCherry (AY678264). In each of the synthetic genes,
fusion partners were joined by an alanine (ala-ala-
ala) linker region. Full details of each synthetic gene
are shown in Table 1, and sequences of each synthetic
gene are shown in Supplementary File 1.
To produce DNA vaccines, each synthetic gene was
PCR amplified using CloneAmp HiFi PCR premix
(Takara, Shiga, Japan) and directionally cloned into
the XhoI site of pVAX1 (Thermo Fisher Scientific,
Waltham, MA, USA) using the In-Fusion HD cloning
kit (Takara, Shiga, Japan), according to the manufac-
turer’s instructions. All synthetic IL21::Dg-CatD-1::
mCherry fusion genes were sequenced after gene syn-
thesis (Thermo Fisher Scientific, Waltham, MA,
USA), and re-sequenced using Sanger sequencing
after cloning into pVAX1 to ensure correct orientation
of each of the genes. Sequence data were edited and
assembled into contiguous sequence using Contig
Express module in Vector Nti (version 11) (Thermo
Fisher Scientific, Waltham, MA, USA). For both pilot
and long-term vaccine trials, endotoxin-free plasmid
DNA for pVAX1 DNA vaccines (Constructs 1–3)
was isolated using NucleoBond PC 10000 EF DNA
purification kit (Macherel-Nagel, Düren, Germany)
and quantified using a NanoDrop ND-1000 spectro-
photometer (Thermo Fisher Scientific, Waltham, MA,
USA). Prior to DNA vaccination, purified pVAX1 vac-
cine DNA (Constructs 1–3) and negative control DNA
(empty pVAX1 DNA) were validated by transfection of
HEK-293 cells, and mCherry fluorescence monitored
using a Nikon fluorescence microscope and images
captured with a Nikon DXM1200F digital camera.
Generation of transgenic Eimeria tenella
expressing Dg-CatD-1::mCherry
A synthetic Dg-CatD-1::mCherry reporter fusion gene
was designed for expression in E. tenella to allow fluor-
escence detection of Dg-CatD-1::mCherry protein in
transformed parasites. The Dg-CatD-1 coding
sequence (HE565350) without the N-terminal signal
sequence and stop codon (corresponding to 49–
1150 bp of the Dg-CatD-1 coding sequence) was
fused to an in-frame C-terminal mCherry reporter
(AY678264) via an alanine (ala-ala-ala) linker region,
and included a C-terminal 6x-His-tag and glycopho-
sphatidyl inositol (GPI) signal from E. tenella surface
antigen SAG D09 (AIR91965). The synthetic gene
was codon optimized for E. tenella (http://www.kaz
usa.or.jp/codon/cgi-bin/showcodon.cgi?species = 5802
&aa = 1&style = GCG), and included a 5′ XbaI site and
3′ BglII site to facilitate cloning into Eimeria transform-
ation vectors. The sequence of the synthetic gene is
shown in Supplementary File 1.
The synthetic Dg-CatD-1::mCherry reporter fusion
gene was used to produce E. tenella transformation
vectors for: (i) cytoplasmic expression of Dg-CatD-1::
mCherry; (ii) secreted expression of Dg-CatD-1::
mCherry and (iii) GPI-anchored expression of Dg-
CatD-1::mCherry. To produce transformation vectors
for cytoplasmic and secreted expression of Dg-CatD-
1::mCherry the synthetic Dg-CatD-1::mCherry reporter
fusion gene was PCR amplified using MyTaq DNA
polymerase (Bioline, Memphis, TN, USA) with a for-
ward primer with an XbaI site (5′-CATT-
CAAAATGTCTAGAGACCTG-3′), and a reverse
primer with a BglII site and stop codon (5′-CGTA-
GATCTTTAGTGGTGGTGGTGGTGG-3′); both
restriction enzyme sites are underlined and the stop
codon shown in bold. The PCR product was cloned
using the pGEM-T Easy vector system (Promega,
Madison, WI, USA), according to the manufacturer’s
instructions, fully sequenced (GATC Biotech, Ebers-
berg, Germany) and sequence data assembled into a
contiguous sequence using CLC Main Workbench
(Qiagen, Venlo, The Netherlands). The sequenced cod-
ing region was digested with XbaI and BglII and cloned
into the respective sites of either: p5M2-mChe (Maru-
gan-Hernandez et al., 2017) to produce “Cytoplasmic
Dg-CatD-1::mCherry” E. tenella transformation vec-
tor; or p5M2-SP2-mChe (Marugan-Hernandez et al.,
2017) to produce “Secreted Dg-CatD-1::mCherry”
E. tenella transformation vector. The GPI-anchored
Dg-CatD-1::mCherry variant was produced by digest-
ing the original (unamplified) Eurofins synthetic Dg-
CatD-1::mCherry reporter fusion gene with XbaI and
BglII and cloned into the respective sites of p5M2-
SP2-mChe-GPI to produce “GPI-anchored Dg-CatD-
1::mCherry”. All Eimeria p5M2 transformation vectors
used here, were generated in a previous study (Maru-
gan-Hernandez et al., 2017), and were a kind gift
from Virginia Marugan-Hernandez (Royal Veterinary
College, UK).
For transformation of E. tenella Wisconsin strain
(McDougald & Jeffers, 1976), oocysts were propagated
in 3–4 week old specific pathogen free (SPF) Light Sus-
sex or Lohmann Selected Leghorn chickens (supplied
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by Millennium Hatchery, Studley, UK) using estab-
lished techniques (Long et al., 1976). Oocysts were
recovered and sporulated, then sporozoites were pur-
ified through columns of nylon wool and DE-52,
using standard methods (Schmatz et al., 1984; Shirley
et al., 1995). Sporozoites transformed with 10 µg PsiI
linearized p5M2-Dg-CatD-1::mCherry transfection
plasmids (Plasmids 1–6) by restriction enzyme-
mediated integration (REMI) transfection using the
Nucleofector 4D system (Lonza, Basel, Switzerland)
according to Marugan-Hernandez et al. (2017). Trans-
formation vectors included: p5M2-Dg-CatD-1::
mCherry, for cytoplasmic expression of Dg-CatD-1::
mCherry; p5M2-SP2-Dg-CatD-1::mCherry, for
secreted expression of Dg-CatD-1::mCherry; and
p5M2-SP2-Dg-CatD-1::mCherry-GPI, for GPI-
anchored expression of Dg-CatD-1::mCherry. For con-
trol E. tenella populations, sporozoites were excysted
and transformed as described above using p5M2 trans-
formation vectors without the Dg-CatD-1 coding
sequence (control vectors included: p5M2-mChe;
p5M2-SP2-mChe and p5M2-SP2-mChe-GPI). To
obtain stable transgenic populations, transfected spor-
ozoites were used for cloacal administration in birds
(12–24 × 103 sporozoites/bird). Oocysts were harvested
7 days after infection, sporulated and used for sub-
sequent in vivo passages after population enrichment
for fluorescent parasites by FACS (BD FACS Aria
III) (Marugan-Hernandez et al., 2016). A full list of
transgenic E. tenella strains generated in this study is
shown in Table 1.
Dg-CatD-1 pilot (P) immunization trial
A pilot vaccination trial was designed to compare cir-
culating serum anti-Dg-CatD-1 IgY antibody levels in
Hy-Line Brown hens after Dg-CatD-1 antigen delivery
by: (i) vaccination with purified rDg-CatD-1 formu-
lated in Montanide™ ISA 71 VG; (ii) vaccination
with DNA for transient expression of Dg-CatD-1::
mCherry; or (iii) oral vaccination with transgenic
E. tenella expressing Dg-CatD-1::mCherry. The pilot
trial was performed under specific pathogen free
(SPF) conditions and ran for 8 weeks. Prior to the
start of the trial, 72× one-day-old chicks (supplied by
Millennium Hatchery, Studley, UK) were co-housed
for 8 days in a loose-litter floor pen (diameter 2.4 m)
with layer mash and water provided ad libitum. At
the beginning of the trial (experimental day 0, eight
days of age) six groups of six chicks were randomly
selected, assigned to groups P7-P12, and housed in
loose-litter floor pens of 1.0 m diameter. The remain-
ing chicks, representing groups P1-P6, were co-housed
in the original 2.4 m diameter pen. All chicks were
wing-tagged to facilitate identification. All groups
received a standard layer mash and water ad libitum
throughout the trial. Blood samples were taken from
two birds per group prior to each treatment and at
intervals throughout the trial. Groups received the fol-
lowing treatments:
Groups P1 & P2. Recombinant protein vaccination
Each bird from the protein vaccination group (Group
P1), received three doses of 50 µg rDg-CatD-1 in Mon-
tanide™ ISA 71 VG via intramuscular (IM) injection
into the thigh at days 2, 12, and 29 of the trial. The
adjuvant-only negative control group (Group P2)
received equivalent injections with 10 mM Tris-HCl
(pH 7.4), 0.5 M NaCl in Montanide™ ISA 71 VG.
Groups P3 – P6. DNA vaccination
Each bird was vaccinated three times with 56 µg DNA
vaccine with 1 mg/kg bupivacaine via IM injection into
the thigh at days 2, 12, and 29 of the trial. Group P3
birds were vaccinated with DNA Construct 1; Group
P4 birds were vaccinated with DNA Construct 2;
Group P5 birds were vaccinated with DNA Construct
3. Details of all DNA constructs are shown in Table
1. The empty vector negative control group (Group
P6) received equivalent injections with 56 µg pVAX1
(empty vector) with 1 mg/kg bupivacaine.
Groups P7 – P12. E. tenella – Dg-CatD-1::mCherry
oral challenge
Each bird was orally infected three times with E. tenella
Dg-CatD-1::mCherry or the appropriate control
E. tenella population, with each bird receiving 1000,
3000 and 5000 oocysts at days 2, 12, and 22 of the
trial, respectively. Groups P7, P9 and P11 were infected
with the experimental E. tenella Populations 1, 3, or 5,
respectively. Group P8, P10 and P12 were infected with
the control E. tenella Populations 2, 4, or 6,
Table 1. Summary of Dg-CatD-1 delivery platforms.
Vaccine delivery Identifier Description Native Dg-CatD-1 SP removed?a Codon optimized [species]
Recombinant protein rDg-CatD-1 Dg-CatD-1 Yes No
DNA vaccine Construct 1 IL21::Dg-CatD-1::mCherry No Yes [Gallus gallus]
Construct 2 IL21::Dg-CatD-1::mCherry Yes Yes [Gallus gallus]
Construct 3 IL21::Dg-CatD-1::mCherry Yes No
E. tenella Population 1 Cytoplasmic Dg-CatD-1::mCherry Yes Yes [E. tenella]
Population 2 Cytoplasmic mCherry Yes [E. tenella]
Population 3 Secreted Dg-CatD-1::mCherry Yes Yes [E. tenella]
Population 4 Secreted mCherry Yes [E. tenella]
Population 5 GPI-anchored Dg-CatD-1::mCherry Yes Yes [E. tenella]
Population 6 GPI-anchored mCherry Yes [E. tenella]
aDg-CatD-1 is a predicted secreted protein, with native signal peptide (SP) predicted at amino acids 1–16.
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respectively. Details of all transgenic Eimeria Popu-
lations are shown in Table 1.
Dg-CatD-1 long-term immunization trial
To investigate longevity of the immune response in
immunized laying hens, a longer-term trial was per-
formed under SPF conditions for 28 weeks. At the
beginning of the trial (experimental day 0, eight days
of age), 80× one-day-old chicks (supplied by Millen-
nium Hatchery, Studley, UK) were randomly assigned
to eight groups (Group L1–L8) of 10 and housed in a
loose-litter floor pen (diameter 1.6 m) with layer
mash and water provided ad libitum. Blood samples
were taken from two birds per group prior to each
treatment and throughout the trial. Groups received
the following treatments:
Group L1 & L2. Recombinant protein vaccination
Each bird from the protein vaccination group (Group
L1), received four injections with 50 µg rDg-CatD-1
in Montanide™ ISA 71 VG via IM injection into the
thigh at days 3, 13, 30 and 177 of the trial. The adju-
vant-only negative control group (Group L2) received
equivalent injections with 10 mM Tris-HCl (pH7.4),
0.5 M NaCl in Montanide™ ISA 71 VG.
Group L3 & L4. DNA vaccination
Each bird from the DNA vaccination group (Group
L3), received four injections with 120 µg DNA vaccine
Construct 3 with 1 mg/kg bupivacaine via IM injection
into the thigh at days 3, 13, 30 and 177 of the trial.
Details of all DNA constructs are shown in Table 1.
The empty vector negative control group (Group L4)
received equivalent injections with 120 µg pVAX1
(empty vector) with 1 mg/kg bupivacaine.
Group L5 & L6. DNA vaccination prime/
recombinant protein vaccination boost
Each bird from the DNA vaccination prime/recombi-
nant protein vaccination boost (Group L5), received
two injections of 120 µg DNA vaccine Construct 3
with 1 mg/kg bupivacaine via IM injection into the
thigh at days 3 and 13 of the trial and injections of
50 µg rDg-CatD-1 in Montanide™ ISA 71 VG via
IM injection into the thigh at days 30 and 177 of the
trial. The control group (Group L6) received two injec-
tions with 120 µg pVAX1 (empty vector) with 1 mg/kg
bupivacaine via IM injection into the thigh at days 3
and 13 of the trial and two injections of 50 µg rDg-
CatD-1 in Montanide™ ISA 71 VG via IM injection
into the thigh at days 30 and 177 of the trial.
Group L7 & L8. Eimeria tenella – Dg-CatD-1::
mCherry oral challenge
Each bird from the Eimeria challenge group (Group L7),
received four oral administrations of E. tenella Popu-
lation 1, with each bird receiving 1000, 3000, 5000 and
10,000 oocysts at days 3, 13, 23 and 72 of the trial. Con-
trol birds (Group L8) each received equivalent doses of
E. tenella Population 2. For all Eimeria challenged
birds, cage litter was replaced at day 59 of the trial.
Evaluation of immune responses to Dg-CatD-1
Levels of serum anti-Dg-CatD-1 IgY were monitored
throughout the pilot and long-term trials by ELISA.
Microtitre plates were coated overnight at 4°C with
50 µl rDg-CatD-1 (10 μg/ml in 50 mM bicarbonate/
carbonate coating buffer, pH 9.6). Plates were washed
six times with phosphate-buffered saline with
TWEEN20 (PBST; 137 mM NaCl, 2.7 mM KCl,
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 0.1% v/v
TWEEN20), and then blockedwith 10% soyamilk pow-
der in Tris-buffered saline with TWEEN20 (TBST;
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% v/v
TWEEN20) for 2 h at room temperature. After wash-
ing, plates were incubated with 50 μl sera (diluted
1:1600 in TBST) and incubated for 1 h at room temp-
erature. Plates were washed again and incubated with
50 μl rabbit anti-chicken IgY-peroxidase conjugate
(Sigma-Aldrich Co Ltd, Dorset, UK) at 1:30,000 in
TBST for 1 h at room temperature. Plates were washed,
and specifically bound antibodies were detected by the
addition of 50 μl SIGMAFAST™ OPD (Sigma-Aldrich
Co. Ltd, Dorset, UK) to each well. After 20 min in the
dark, the colour reaction was stopped by addition of
25 μl of 2.5 M H2SO4 to each well and the OD values
read at 490 nm. Each serum sample from individual
birds was assayed in duplicate.
On-bird D. gallinae vaccine trial
The Dg-CatD-1 vaccine trial was performed under SPF
conditions and ran for 37 days. Prior to the start of the
trial, 10× 19-week-old Hy-Line Brown pullets were ran-
domly assigned to two groups (Group V1 and Group
V2) of five. Throughout the trial birds were housed in
an enclosed, loose-litter floor pen of 2.1 m × 0.9 m
with natural lighting. All groups received layer mash
and water ad libitum throughout the trial; perches
and nest boxes were provided. At the beginning of the
trial (experimental day 0, 17 weeks of age) and through-
out the trial, blood samples were taken from birds in
each group. Each bird from the Dg-CatD-1 protein vac-
cination group (Group V1), received two injections of
50 µg rDg-CatD-1 in Montanide™ ISA 71 VG via IM
injection into the breast at day 2 and day 16 of the
trial. The adjuvant-only negative control group
(Group V2) received equivalent injections with
10 mM Tris-HCl (pH7.4), 0.5 M NaCl in Montanide™
ISA 71 VG.
For on-bird D. gallinae feeding trials, mixed-stage
and mixed-sex mites were collected from commercial
egg-laying facilities and stored in vented 75 cm2 tissue
culture flasks (Corning, NY, USA) at room temperature
(RT) for seven days, after which they were stored at 4°C
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for 3 weeks without access to food. On-bird feeding
trials were performed, according to methods previously
described (Nunn et al., 2019). Briefly, sealed mesh feed-
ing devices were constructed from 105 μm aperture
width, 63 μm depth polyester mesh, and each mesh
feeding device was filled with 100 conditioned adult
femaleD. gallinaemites. Prior to feeding assays, feathers
were plucked from the outer thigh of each hen, and a
single feeding pouch containing mites was placed on
the plucked thigh and held in place using Leucoplast
tape and further secured using a cohesive bandage
(Central Medical Supplies Ltd., Pontefract, UK),
according to methods described by Nunn et al. (2019).
Feeding devices were left on the birds for 3 h, after
which devices were removed and engorged fed mites
were recovered and transferred to individual wells of a
96-well tissue culture plate (Costar, Corning, NY,
USA), sealed with AeraSeal tape (Sigma-Aldrich Co.
Ltd, Dorset, UK). Plates were incubated at 25°C with
85% relative humidity, and mites were monitored
daily over 8 days and scored for survival and cumulative
egg production. The experiment was repeated three
times at day 28, day 30 and day 32 of the experiment
(at peak levels of serum anti-Dg-CatD-1 IgY), with
each experiment using fresh batches of conditioned
adult female D. gallinae mites and the same Dg-CatD-
1 vaccinated birds (GroupV1) and adjuvant-only vacci-
nated birds (Group V2).
Statistical analyses
Analysis of antibody levels induced by different modes
of immunization in the pilot and long-term vaccine
trials, analysis of anti-Dg-CatD-1 IgY antibody titres
in egg yolks, and analysis of mite feeding rates on vac-
cinated and unvaccinated chickens were analysed using
GraphPad Prism version 8.0.0 forWindows (GraphPad
Software, La Jolla, CA, USA, www.graphpad.com).
Datasets were analysed using either: Student’s t-test,
one-way ANOVAwith Dunnett’s multiple comparison
test, or Mann–Whitney U test (as indicated). P values
of <0.05 were considered significant. For the analysis
of numbers of eggs per mite in the on-hen vaccine
trial study, data were analysed with a Poisson general-
ized linear mixed model (GLMM) including an offset to
account for the number of fed mites.
Results
Expression and validation of recombinant Dg-
CatD-1 vaccine antigen
To investigate antigen delivery platforms in laying
hens, recombinant vaccine antigen Dg-CatD-1 was
expressed in E. coli and purified as an insoluble protein
(Figure 1(A)); encoded as a Dg-CatD-1::mCherry
fusion in DNA vaccines (Figure 1(B)); or expressed
as a Dg-CatD-1::mCherry fusion in transgenic
E. tenella parasites (Figure 1(C)).
In E. coli, rDg-CatD-1 was expressed as an insoluble
protein at approx. 60 mg/litre cell culture. Purified
refolded rDg-CatD-1 migrated as a 42 kDa protein
when analysed by reducing SDS-PAGE, in agreement
with its calculated molecular weight (Figure 1(A)). To
aid detection of the expressed antigen in DNA vaccines
and transformed Eimeria parasites, Dg-CatD-1 was
fused at the C-terminus to an in-frame mCherry repor-
ter tag. All vaccine constructs are detailed in Table 1.
Prior to DNA vaccination of hens, expression of the
encoded transgenes in each DNA vaccine construct
was validated by transfection and expression in HEK
293 cells (Figure 1(B)). For DNA vaccine Constructs
1–3, production of rDg-CatD-1::mCherry was
confirmed by the presence of the fused mCherry repor-
ter by fluorescence microscopy (Figure 1(B)). E. tenella
transformants were selected by FACS enrichment of
mCitrine expressing parasites (background transfection
control). After five passages, the number of mCitrine
Figure 1. Expression of rDg-CatD-1 and rDg-CatD-1::mCherry. (A) SDS-PAGE analysis of purified refolded rDg-CatD-1 with Coomas-
sie staining. Arrow indicates purified rDg-CatD-1 at 42 kDa. (B) Validation of Dg-CatD-1::mCherry DNA vaccine constructs in HEK 293
cells transfected with Construct 1 (panel 1), Construct 2 (panel 2) and Construct 3 (panel 3). Negative control cells (panel 4) were
transfected with empty pVAX1. In each panel localization of mCherry reporter (red) is shown. Scale bar is 50 µm. (C) Expression of
Dg-CatD-1::mCherry in transgenic E. tenella oocysts. Panels 1–6 represent E. tenella Populations 1–6, respectively. In each panel
localization of mCherry (red) and mCitrine (green) reporters is shown. Scale bar is 10 µm. Colour online only.
AVIAN PATHOLOGY 7
positive transformants was increased between 10- and
20-fold. Positive transformants were selected by FACS
sorting before each trial, ensuring >95% of inoculated
oocysts were expressing the transgene. All transgenic
Eimeria parasites generated in this study are detailed
in Table 1. Expression of Dg-CatD-1 protein was
confirmed by detection of the fused mCherry reporter
by fluorescence microscopy (Figure 1(C)).
Characterization of Dg-CatD-1 haemolytic
activity
Purified refolded rDg-CatD-1 is an enzymatically
active aspartyl proteinase, with detectable haemoglobin
digestion activity. High levels of protease activity were
detected in acidic conditions (pH 2–5), with a pH opti-
mum at pH 4. In comparison, D. gallinae soluble
protein extracts also had high levels of haemoglobin
digestion protease activity in acidic conditions, with a
comparable pH profile and pH optimum to rDg-
CatD-1 (Figure 2(A)). Protease activity of both rDg-
CatD-1 and D. gallinae soluble protein extracts were
inhibited by 2 µM Pepstatin A (Figure 2(B)).
Localization of Dg-CatD-1 in D. gallinae whole
mite sections
Antiserum raised against rDg-CatD-1 was first vali-
dated in western blot experiments. Rabbit anti-rDg-
CatD-1 antiserum was found to specifically bind pur-
ified rDg-CatD-1 (Supplementary Figure 1, Lanes 1
and 2) as well as native Dg-CatD-1 in soluble protein
extracts derived from both fed and starved
D. gallinae mites (Supplementary Figure 1, Lanes 3, 4
and 5). Control western blots probed with pre-immune
sera from the same rabbit showed no non-specific
cross-reactivity (Supplementary Figure 1). For localiz-
ation experiments, consecutive sections of fixed, wax-
embedded mites were probed with either rabbit
anti-rDg-CatD-1 sera or rabbit pre-immune sera
(Figure 3). Mite tissue sections probed with anti-rDg-
CatD-1 antisera showed ubiquitous staining, with the
exception of ovary tissue in female mites (Figure 3
(A)). As a control, a consecutive section of the same
mite probed with pre-immune sera showed no non-
specific antibody staining (Figure 3(B)).
Comparative analysis of anti-Dg-CatD-1 IgY
levels – pilot study
Recombinant protein vaccination
Group P1 birds immunized three times (V1, V2, V3)
with 50 µg rDg-CatD-1 in Montanide™ ISA 71 VG
Figure 2. Haemoglobinolytic protease activity analysis of Dg-CatD-1. (A) Activity of refolded rDg-CatD-1 and soluble D. gallinae
protein extract at pH 2 – pH 7 (as indicated in the figure). (B) Activity of refolded rDg-CatD-1 and soluble D. gallinae protein extract
at pH 4 in the presence (+) or absence (-) of pepstatin A (2 µM final concentration). Each value is the mean ± SEM, n = 4.
Figure 3. Immunohistochemical localization of Dg-CatD-1 in
D. gallinae. Sequential D. gallinae tissue sections (5 µm thick-
ness) were probed with either: (A) rabbit polyclonal anti-Dg-
CatD-1 sera; or (B) pre-immune rabbit sera. Specifically
bound antibodies were detected using EnVision+ System-
HRP (DAB) (Dako) and counterstained with haematoxylin. Ov,
ovary; hm, haematin granules. Scale bar is 125 µm.
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generated a specific serum anti-Dg-CatD-1 IgY
response, with a peak serum IgY level 10 days after
V2 (Figure 4(A)). Anti-Dg-Cat-1 IgY levels remained
above levels observed in adjuvant-only immunized
birds (Group P2) for at least 22 days post V3 (Figure 4
(A)). Adjuvant-only control birds (Group P2) did not
generate anti-Dg-CatD-1 IgY antibodies (Figure 4
(A)).
DNA vaccination
Group P3, P4 and P5 birds were vaccinated three
times with 56 µg DNA Constructs 1, 2 and 3,
respectively. All DNA vaccine constructs (Con-
structs 1–3) are detailed in Table 1. Birds vaccinated
with DNA vaccine Construct 1 did not generate an
anti-Dg-CatD-1 IgY response and were comparable
to control birds vaccinated with empty pVAX1
DNA vector. Birds vaccinated with DNA vaccine
Construct 2 and DNA Construct 3 had elevated
sera anti-Dg-CatD-1 IgY level 7–22 days after V3
(Figure 4(B,C)). However, anti-Dg-CatD-1 IgY levels
at 22 days post V3 were not significantly different to
control birds immunized with empty pVAX1 DNA
vector (one-way ANOVA with Dunnett’s multiple
comparison test, n = 4).
Eimeria tenella – Dg-CatD-1::mCherry oral
challenge
Group P7, P9 and P11 birds were immunized orally
with Dg-CatD-1 expressing transgenic E. tenella popu-
lations 1, 3 or 5, respectively. All transgenic E. tenella
parasites (populations 1–6) generated in this study
are detailed in Table 1. Chickens challenged with trans-
genic E. tenella expressing three different variants of
Dg-CatD-1::mCherry, did not generate a specific
anti-Dg-CatD-1 IgY response (Figure 4(D)), and
Figure 4. Comparative analysis of serum anti-Dg-CatD-1 IgY levels during the pilot vaccine trial. Comparative ELISA showing levels
of circulating anti-Dg-CatD-1 IgY antibodies in chicken sera after delivery of Dg-CatD-1 antigen by: (A) recombinant protein vac-
cination; (B) and (C) DNA vaccination; and (D) transgenic Eimeria. Black triangles indicate time points for either rDg-CatD-1 protein
vaccination, Dg-CatD-1 DNA vaccination, or transgenic Dg-CatD-1 Eimeria challenge. Sera in panels (A), (B) and (D) were used at 1/
1600; serum in panel (C) was used at 1/200. Individual data points are shown for each replicate sample. At each time point n = 2,
except day 51 where n = 4. Connecting line represents mean value at each time point.
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showed no difference from control birds immunized
orally with transgenic E. tenella populations expressing
only mCherry (Figure 4(D)).
Comparative analysis of anti-Dg-CatD-1 IgY
levels – long term study
Recombinant protein vaccination
Group L1 birds immunized three times (V1, V2, V3)
with 50 µg rDg-CatD-1 in Montanide™ ISA 71 VG
generated a specific anti-Dg-CatD-1 IgY response,
with a peak serum IgY level 7 days after V2 (Figure 5
(A)). Serum anti-Dg-Cat-1 IgY levels remained above
those observed in adjuvant-only control birds (Group
L2) for at least 100 days post V3 (Figure 5(A)). Adju-
vant-only control birds (Group L2) did not generate
anti-Dg-CatD-1 IgY antibodies (Figure 5(A)). Finally,
a fourth rDg-CatD-1 immunization (V4) at day 177
of the experiment elevated the circulating anti-Dg-
CatD-1 IgY level in immunized birds (Group L1) rela-
tive to adjuvant-only control birds (Group L2). Specific
anti-Dg-CatD-1 antibodies were also detectable in egg
yolks from Group L1 birds at day 64 and day 65 (rela-
tive to first bleed), and were significantly higher than in
control adjuvant-only vaccinated birds (t-test P <
0.0001) (Figure 6).
DNA Vaccination
Group L3 birds vaccinated four times (V1, V2, V3 and
V4) with 120 µg DNA Construct 3 did not generate an
anti-Dg-CatD-1 IgY response and were comparable to
negative control birds (Group L4) vaccinated with con-
trol DNA Construct 4 (Figure 5(B)).
DNA vaccination prime/recombinant protein
vaccination boost
Group L5 birds vaccinated twice (V1, V2) with 56 µg
DNA Construct 3 and then once (V3) with rDg-
CatD-1 in Montanide™ ISA 71 VG generated a
specific anti-Dg-CatD-1 IgY response after the protein
boost immunization (Figure 5(C)). However, vacci-
nation with DNA Construct 3 did not prime a
response, and comparable anti-Dg-CatD-1 IgY levels
were observed in negative control birds vaccinated
with pVAX1 followed by a rDg-CatD-1 protein boost
immunization (Figure 5(C)).
Eimeria tenella – Dg-CatD-1::mCherry oral
challenge
The pilot study demonstrated that birds challenged
with E. tenella expressing three different variants of
Dg-CatD-1::mCherry did not generate a specific anti-
Dg-CadD-1 IgY response. As an extension of this pre-
liminary trial, we performed an additional long-term
Figure 5. Comparative analysis of serum anti-Dg-CatD-1 IgY levels during the long-term vaccine trial. Comparative ELISA showing
levels of circulating anti-Dg-CatD-1 IgY antibodies in chicken sera after delivery of Dg-CatD-1 antigen by: (A) recombinant protein
vaccination; (B) DNA vaccination; (C) DNA vaccination prime followed by a recombinant protein boost; and (D) transgenic Eimeria.
Black triangles indicate rDg-CatD-1 protein vaccination; dark grey triangles indicate Dg-CatD-1 DNA vaccination; light grey triangles
indicate transgenic Dg-CatD-1 Eimeria inoculation; open triangle indicates litter change for chickens receiving transgenic Eimeria. All
sera were tested at 1/1600. Individual data points are shown for each replicate sample. At each time point n = 2, except day 191
where n = 4–8. Connecting line represents mean value at each time point.
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trial to test whether prolonged exposure to E. tenella
expressing Dg-CatD-1::mCherry was sufficient to gen-
erate a detectable anti-Dg-CatD-1 IgY response. For
the long-term study, Group L7 and L8 birds adminis-
tered with transgenic E. tenella Population 1 or 2,
respectively, generated an anti-Eimeria IgY response,
confirming establishment of E. tenella infection (Sup-
plementary Figure 2). However, birds infected with
E. tenella test Population 1 did not generate an anti-
Dg-CatD-1 IgY response and were comparable to
negative control birds infected with control E. tenella
Population 2 expressing only mCherry (Figure 5(D)).
On-bird D. gallinae vaccine trial
Birds immunized twice (V1 and V2) with 50 µg rDg-
CatD-1 in Montanide™ ISA 71 VG generated a
specific serum anti-Dg-CatD-1 IgY response, with
similar dynamics to those in the pilot vaccine trial
(Figure 4) and the long-term vaccine trial (Figure 5).
Peak serum anti-Dg-CatD-1 IgY levels were observed
13 days after V2 (Figure 7(A)), while birds immunized
with only adjuvant did not generate anti-Dg-CatD-1
IgY antibodies. On-bird D. gallinae feeding trials,
where conditioned adult female mites in mesh pouches
were fed on either Dg-Cat-D-1 vaccinated or control
birds, were conducted between days 28–32 (relative
to the first bleed), at peak levels of serum anti-Dg-
CatD-1 IgY antibodies (Figure 7(B)). Feeding rates of
female D. gallinae mites on chickens vaccinated with
either rDg-CatD-1 or adjuvant only control were
62% ± 5.4 (n = 12) and 70% ± 7.1 (n = 10), respectively,
with no statistically significantly difference between
groups (Mann–Whitney U test, P = 0.2276). The total
number of fed female mites recovered varied within
group and experiment, and the total number of recov-
ered fed female mites for the three repetitions of the
experiment were as follows: rDg-CatD-1 n = 186, 337
and 151; Control n = 232, 258 and 146. (Figure 7(B)).
Cumulative mite egg production per fed mite over 7
days was analysed using a Poisson GLMM including
an offset to account for the varied number of fed
mites. The results showed statistically significant differ-
ences between treatment groups, with fed mites from
the rDg-CatD-1 vaccinated group (Group V1) produ-
cing fewer eggs than mites which had fed on control
hens (Group V2) (P = 0.0033, LRT P = 0.01456).
Discussion
We have characterized the activity and localization of
the aspartyl proteinase Dg-CatD-1 in the poultry red
mite, demonstrating that Dg-CatD-1 digests haemo-
globin, and has a ubiquitous localization, with the
exception of the ovary, in female mite tissues. In
blood-feeding mites, haemoglobin digestion takes
place in intracellular vesicles through the combined
activities of lysosomal endopeptidases Cathepsin D
(Dg-CatD-1) and Cathepsin L (Nisbet & Billingsley,
2000; Filimonova, 2013; Pritchard et al., 2015). While
Dg-CatD-1 is predicted to function in the gut as a
digestive proteinase, based on its localization, it is
also likely to function in lysosomes throughout mite
tissues. Using Dg-CatD-1 as a model vaccine antigen,
we analysed different methods of delivering this
protein as a vaccine to chickens in order to induce
high and sustained serum antibody levels, and demon-
strated its potential for inclusion in a vaccine to control
red mite infestations.
Almost every licensed vaccine available on the
market for use against infectious agents confers pro-
tection by inducing pathogen-/antigen-specific anti-
body production in the host (reviewed by Rappuoli
et al., 2016). The efficacy of vaccine-induced antibody
responses against eukaryotic haematophagous para-
sites is established for some ecto- and endo-parasites
(e.g. see Nisbet & Huntley, 2006; Nisbet et al.,
2016). However, the requirement for long-lasting
(>1 year) immunity in commercial laying hens is a
particular challenge, given the scale of these
Figure 6. Comparative analysis of egg yolk anti-Dg-CatD-1 IgY antibodies from the long-term vaccine trial. Comparative ELISA
showing levels of anti-Dg-CatD-1 IgY antibodies in egg yolk from birds in treatment Groups L1 – L8 (as indicated in the figure).
Eggs were collected from each group at days 64 and 65 relative to the first bleed, and diluted yolks from individual eggs were
used at 1/1600. Each bar represents mean ± SEM, n = 3–10. Non-significant (ns) and significant differences (****) between treat-
ment groups are shown (t-test, P < 0.0001).
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operations and associated difficulties in administering
booster vaccinations by injection during the laying
cycle. For this reason, we investigated three different
methods of vaccine administration to attempt to
gain high, sustained levels of antigen-specific circulat-
ing antibody.
Montanide™ ISA 71 VG has been used previously
to immunize hens with Eimeria recombinant profilin
protein because of the enhanced immune repertoire
generated by this adjuvant (Jang et al., 2013). In the
current study, this method of antigen administration
proved to be the most superior for inducing antigen-
specific serum IgY. A series of three immunizations,
administered to hens before 6 weeks of age, led to
high antigen-specific serum IgY levels which were sus-
tained for >100 days.
Vaccination of chickens with DNA vaccines encod-
ing Dg-CatD-1 fused with chicken IL-21 and mCherry
reporter did not induce a significant level of antigen-
specific antibodies, unless boosted by immunization
with the rDg-CatD-1 protein, though antigen-specific
antibody levels were short-lived following the booster.
The Gallus gallus IL-21 coding sequence was included
in the construct of the DNA vaccines, as it has been
shown to facilitate specific humoral responses in
DNA vaccines against Toxoplasma (Chen et al.,
2014). Although a number of interleukins had shown
some promise, IL-21 was one of the few Gallus gallus
interleukin genes available in a public database at the
time of design of DNA constructs in this project. IL-
21 had shown some promise to induce B-cell differen-
tiation into antibody-secreting plasma cells (Ettinger
et al., 2005) and to increase levels of humoral responses
after DNA-vaccination in synergy with other interleu-
kins after being included in DNA constructs (Li et al.,
2014). Since higher levels of antibody production
towards the mite protein Dg-CatD-1 was the purpose
of this study, we hoped these additional gene fragments
could facilitate humoral responses in our experiments.
For IL-21, there is now conflicting evidence suggesting
Figure 7. D. gallinae feeding trial on hens vaccinated with rDg-CatD-1. (A) Comparative ELISA showing levels of circulating anti-Dg-
CatD-1 IgY antibodies in chicken sera after vaccination with rDg-CatD-1 in Montanide ISA 71 VG, or adjuvant only control. Black
triangles indicate vaccination time points. All sera were tested at 1/1600. Individual data points are shown for each replicate sample
(n = 5), with exception of the control group (n = 4) as a bird was removed from the trial due to health issues unrelated to the study.
Following vaccination, a D. gallinae on-bird feeding trial was conducted on day 28, day 30 and day 32 (shaded grey). (B) Egg pro-
duction of D. gallinae mites after feeding on birds vaccinated with either rDg-CatD-1 or adjuvant only (control). Eggs per fed mite in
assay is shown at 196 h post-feeding time point. The feeding assay was repeated three times (assay 1–3) using the same vaccinated
birds. Individual data points are shown for each assay with mean ± SEM (n = 15, rDg-CatD-1 group; n = 12, control treatment
group).
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that although, it may facilitate humoral responses in
some cases, the opposite may also occur (Leonard
and Wan, 2016). The failure to provoke an anti-Dg-
CatD-1 humoral response in these studies may there-
fore be explained by this double- edged effect of IL-21.
Oral inoculation of birdswith transgenic populations
of E. tenella expressing a selected exogenous antigen has
been shown to confer partial protection against chal-
lenge with E.maxima, with levels of efficacy comparable
to those obtained using recombinant protein or DNA
vaccines (Pastor-Fernandez et al., 2018). However,
this method of antigen delivery did not generate a
specific humoral immune response against rDg-CatD-
1 in the present study, possibly due to low levels of anti-
gen expression or misfolding of the expressed protein,
among other recurrent issues when ectopically expres-
sing proteins in evolutionarily unrelated organisms.
Serial E. tenella infection induces a robust immune
response including elevated serum antibody levels
specific for soluble E. tenella oocyst antigen (Gilbert
et al., 1988). However, while recent studies using trans-
genic E. tenella to deliver vaccine antigens targeting
Campylobacter jejuni, infectious laryngotracheitis
virus or infectious bursal disease virus demonstrated
capacity to induce specific antibody responses, all were
generally low titre and variable between individuals
(Clark et al., 2012; Marugan-Hernandez et al., 2016).
Comparison of these results suggest that current trans-
fection protocols for E. tenella promote more effective
induction of cell-mediated than humoral transgene-
specific immune responses.
Immunization of hens with rDg-CatD-1 in Monta-
nide™ ISA 71 VG resulted in antigen-specific serum
IgY which, when consumed by adult female
D. gallinae feeding on the immunized hens in in vivo
feeding devices, induced an ∼50% reduction in egg
production by the mites (Figure 7(B)). Dg-CatD-1
was selected as a model antigen for our work because
its expression is induced by blood feeding (Bartley
et al., 2012), it is ubiquitously expressed in tissues
accessible to ingested IgY (Figure 3 and Nisbet et al.,
2006) and antibodies to Dg-CatD-1 increased mortality
of D. gallinae in in vitro assays (Bartley et al., 2012). In
other haematophagous parasites, aspartyl proteinases,
including orthologues of Dg-Cat-D1, initiate haemo-
globin digestion and are vital for parasite nutrition
(Williamson et al., 2004). A similar role has been pro-
posed for aspartyl proteinases in D. gallinae marking
them out as important potential vaccine candidates
(Nisbet & Billingsley, 2000; Hamilton et al., 2003).
In this study, we have made substantial progress
towards identifying a method to administer prototype
vaccines for D. gallinae in hens to stimulate long-last-
ing circulating antibody responses. With the recent
publication of the D. gallinae genome (Burgess et al.,
2018), we expect an increase in activity in development
of prototype vaccines for this species. However, for any
vaccine which relies on induction of protective anti-
bodies there is a threshold level of antigen-specific anti-
body below which efficacy is compromised. This
threshold needs to be determined empirically, along
with detailed analysis of the population dynamics of
D. gallinae (see Mul et al., 2017), to establish the
required levels of both antibody and vaccine efficacy
to impact on PRM numbers and to keep parasite num-
bers below the economic threshold of infestation.
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